Dr. John W Winkelman, MD/PhD
Claim this profileMore about John W Winkelman, MD/PhD
Clinical Trial Related
4 years of experience running clinical trials · Led 1 trial as a Principal Investigator · 0 Active Clinical Trials
Treatments John W Winkelman, MD/PhD has experience with
- Pramipexole
Breakdown of trials John W Winkelman, MD/PhD has run
Restless Legs Syndrome
Sleep Disorders
Opioid Use Disorder
Sleep Disorder
Opiate Dependence
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does John W Winkelman, MD/PhD specialize in?
John W Winkelman, MD/PhD focuses on Restless Legs Syndrome and Sleep Disorders. In particular, much of their work with Restless Legs Syndrome has involved treating patients, or patients who are undergoing treatment.
Is John W Winkelman, MD/PhD currently recruiting for clinical trials?
No, John W Winkelman, MD/PhD is not currently recruiting for any clinical trials. This may change in the future, so check back later.
Are there any treatments that John W Winkelman, MD/PhD has studied deeply?
Yes, John W Winkelman, MD/PhD has studied treatments such as Pramipexole.
What is the best way to schedule an appointment with John W Winkelman, MD/PhD?
Apply for one of the trials that John W Winkelman, MD/PhD is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.